Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | KCNJ6 | P48051 | 6/20 | 0.34 |
| ▸ | KCNJ3 | P48549 | 6/20 | 0.34 |
| ▸ | KCNJ5 | P48544 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL287148 | 0.82 | ALDH1A1 (0.33) | APLNRKCNJ6KCNJ3KCNJ5POLB | |
| SCHEMBL27855104 | 0.80 | APLNR (0.31) | APLNRKCNJ6KCNJ3KCNJ5PDE7A | |
| SCHEMBL299982 | 0.77 | CRHR1 (0.35) | CRHR1KDM4EALDH1A1PKM | |
| SCHEMBL286895 | 0.65 | SMN1; SMN2 (0.34) | — | |
| SCHEMBL5373710 | 0.65 | KCNJ6 (0.44) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL661119 | 0.64 | FAAH (0.42) | — | |
| SCHEMBL661852 | 0.63 | CTNNB1 (0.34) | KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL661658 | 0.62 | GRM5 (0.38) | TDP1KDM4EALDH1A1 | |
| SCHEMBL287649 | 0.60 | GRIN2B (0.38) | ALDH1A1 | |
| SCHEMBL7810346 | 0.59 | GRIN2B (0.36) | KMT2APOLBTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102459175-A | Piperidine derivatives for the treatment of diabetes | TORRENT PHARMACEUTICALS LTD | 2012-05-16 | — | — | CN | claimed |
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | claimed |
| CN-102459175-A | Piperidine derivatives for the treatment of diabetes | TORRENT PHARMACEUTICALS LTD | 2012-05-16 | — | — | CN | disclosed |
| EP-2427432-A2 | NOVEL HETEROCYCLIC COMPOUNDS | Torrent Pharmaceuticals Limited (IN) | 2012-03-14 | — | — | EP | disclosed |
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | disclosed |
| WO-2010128528-A2 | NOVEL HETEROCYCLIC COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | AGER, REN, AGT | APLNR 707/4885KCNJ6 2854/4885KCNJ3 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.